Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Ordinary Shares, nominal value Euro 0.12 per share
-
Shares outstanding
-
114,390,553
-
Total 13F shares
-
116,368,291
-
Share change
-
+5,189,233
-
Total reported value
-
$2,107,516,504
-
Put/Call ratio
-
388%
-
Price per share
-
$18.11
-
Number of holders
-
130
-
Value change
-
+$92,203,096
-
Number of buys
-
82
-
Number of sells
-
50
Institutional Holders of NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value Euro 0.12 per share (NAMS) as of Q2 2025
As of 30 Jun 2025,
NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value Euro 0.12 per share (NAMS) was held by
130 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
116,368,291 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., Bain Capital Life Sciences Investors, LLC, FCPM III SERVICES B.V., RA CAPITAL MANAGEMENT, L.P., Capital World Investors, VIKING GLOBAL INVESTORS LP, DEERFIELD MANAGEMENT COMPANY, L.P., WELLINGTON MANAGEMENT GROUP LLP, ADAGE CAPITAL PARTNERS GP, L.L.C., and JENNISON ASSOCIATES LLC.
This page lists
130
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.